U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula 2C3H5O2.Zn
Molecular Weight 211.55
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC PROPIONATE

SMILES

[Zn++].CCC([O-])=O.CCC([O-])=O

InChI

InChIKey=XDWXRAYGALQIFG-UHFFFAOYSA-L
InChI=1S/2C3H6O2.Zn/c2*1-2-3(4)5;/h2*2H2,1H3,(H,4,5);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula C3H5O2
Molecular Weight 73.0706
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Originator

Curator's Comment: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
[Reduced thymulin production during occupational exposure to lead].
2005 Jan-Mar
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.
2005 May
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Influence of dietary zinc and copper on digestive enzyme activity and intestinal morphology in weaned pigs.
2006 Dec
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
DNA damaging potential of zinc oxide nanoparticles in human epidermal cells.
2009 Mar 28
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles.
2010 Dec 15
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Patents

Sample Use Guides

single intravenous injection of 50 Units per kg
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:36 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:36 GMT 2025
Record UNII
81PXA87XVC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GYNA-PLEX
Preferred Name English
ZINC PROPIONATE
HSDB   MI  
Systematic Name English
ZINC PROPANOATE
Systematic Name English
PROPANOIC ACID, ZINC SALT
Common Name English
ZINC DIPROPIONATE
Systematic Name English
AV-23636
Code English
PROPANOIC ACID, ZINC SALT (2:1)
Common Name English
AV 23636
Code English
ZINC PROPIONATE [HSDB]
Common Name English
ZINC PROPIONATE [MI]
Common Name English
PROPIONIC ACID, ZINC SALT
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID10890510
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
MERCK INDEX
m11623
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY Merck Index
FDA UNII
81PXA87XVC
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
PUBCHEM
11189
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
CAS
557-28-8
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
ECHA (EC/EINECS)
209-167-6
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
HSDB
1061
Created by admin on Mon Mar 31 17:34:36 GMT 2025 , Edited by admin on Mon Mar 31 17:34:36 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY